Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of the RAGE Inhibitor FPS-ZM1 for Controlling Post-Operative Cerebral Edema in Glioblastoma Patients

NCT07791264 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT07791264
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07791264 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of the RAGE Inhibitor FPS-ZM1 for Controlling Post-Operative Cerebral Edema in Glioblastoma Patients
Lead sponsor
City of Hope Medical Center
Phase
Phase 1
Overall status
Not yet recruiting
Start date
February 17, 2027
Completion date
August 28, 2028
Enrollment
24 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma, malignant glioma, recurrent glioblastoma, recurrent malignant glioma